Hansoh Pharmaceutical Group Company Limited
3692
Classement en actions
#905
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Prix de l'action
$4.40
Capitalisation boursière
$26.66B
Changement (1 jour)
0.00%
Changement (1 an)
-4.79%
Pays
CN
Échange Hansoh Pharmaceutical Group Company Limited (3692)
Catégorie
Healthcare
Ratio P/B pour Hansoh Pharmaceutical Group Company Limited (3692)
Ratio P/B au October 2026 TTM : 4.30
Selon les derniers rapports financiers et le cours de l'action de Hansoh Pharmaceutical Group Company Limited, le ratio cours/valeur comptable actuel (TTM) est 4.30. À la fin de 2023, le ratio P/B était de 3.47.
Historique du ratio P/B pour Hansoh Pharmaceutical Group Company Limited de 2016 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 4.30 | 28.00% |
| 2024 | 3.36 | -3.35% |
| 2023 | 3.47 | 1.44% |
| 2022 | 3.42 | -25.17% |
| 2021 | 4.57 | -56.01% |
| 2020 | 10.40 | 7.03% |
| 2019 | 9.72 | -86.95% |
| 2018 | 74.45 | 213.64% |
| 2017 | 23.74 | -55.98% |
| 2016 | 53.92 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 17.21% |
IN
|
